1. Home
  2. KLTR vs SKYE Comparison

KLTR vs SKYE Comparison

Compare KLTR & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kaltura Inc.

KLTR

Kaltura Inc.

HOLD

Current Price

$1.42

Market Cap

218.0M

Sector

Technology

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.78

Market Cap

29.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLTR
SKYE
Founded
2006
2012
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.0M
29.1M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
KLTR
SKYE
Price
$1.42
$0.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$3.00
$15.00
AVG Volume (30 Days)
439.0K
166.6K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
61.90
N/A
EPS
N/A
N/A
Revenue
$180,854,000.00
N/A
Revenue This Year
$2.96
N/A
Revenue Next Year
$4.96
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.20
N/A
52 Week Low
$1.06
$0.57
52 Week High
$2.26
$5.75

Technical Indicators

Market Signals
Indicator
KLTR
SKYE
Relative Strength Index (RSI) 47.25 47.65
Support Level $1.38 $0.71
Resistance Level $1.56 $0.83
Average True Range (ATR) 0.07 0.06
MACD -0.01 -0.01
Stochastic Oscillator 6.57 39.53

Price Performance

Historical Comparison
KLTR
SKYE

About KLTR Kaltura Inc.

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: